| Liver transplant candidate |
-
•
Perform nutritional screening of all ESLD patients using RFH-NPT at baseline.
-
•
Detailed nutritional assessment if:
-
•
Include SMI-L3 assessment to quantify muscle mass when CT performed for other indications.
-
•
Hand-grip strength and gait speed should be used to assess muscle strength and performance.
-
•
Utilize local population-based cut-offs.
-
•
Dietary recommendation
-
➢
Provide calories up to 1.2–1.3 times the REE (use indirect calorimetry, if available)
-
➢
Total calories: 35–40 kcal/kg/day, 60–70% carbohydrates and 20–30% proteins.
-
➢
BMI based calorie supplementation should be considered in obese.
-
➢
Multiple meals every 5–6 h with nocturnal calories dense snack (50 gm complex carbohydrates, 15 gm protein).
-
➢
While salt restriction is important in patients with ascites, palatability should not be compromised.
-
➢
Supplement vitamins and trace minerals.
-
➢
Oral BCAA can be considered in sarcopenic patients, patient with recurrent HE, or protein intolerance to meet daily protein requirements.
-
•
Prescribe graded, individualized exercise programs (aerobic and resistance) with a target of 150 min/week after assessing safety.
-
•
Minimize iatrogenic fasting for investigations/procedures.
-
•
Role of hormonal therapy and immune-nutrition supplementation remains unclear.
-
•
Periodically reassess nutrition and impact of interventions
-
•
In hospitalized critically ill cirrhosis patients, assess dietary intake daily and supplement using nasogastric feeding if unable to meet requirements orally.
|
| Liver transplant recipients |
|
| Perioperative period |
-
•
Follow ERAS protocol pre-operatively
-
•
Initiate early enteral nutrition within 12–24 h post-operatively
-
•
Gradually up-titrate calorie and protein supplementation.
-
•
Parenteral nutrition is preferable to no nutrition when enteral nutrition is not feasible.
-
•
Standard nutrition formula should be used.
|
| Long-term follow-up |
-
•
Monitor weight and body mass index during follow-up.
-
•
Ensure dietary compliance, exercise, restricted weight gain, and alcohol abstinence.
-
•
Monitor for sarcopenic obesity, diabetes, dyslipidaemia, hypertension, osteodystrophy, and other risks regularly.
-
•
Actively identify and manage immunosuppressant drugs related metabolic derangements and drug interactions.
|